Search results
Jun 20, 2024 · Jazz Pharmaceuticals is focused on improving patients’ lives by identifying, developing, and commercializing products that address unmet medical needs.
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States.
Jun 20, 2024 · The Investor Relations website contains information about Jazz Pharmaceuticals plc's business for stockholders, potential investors, and financial analysts.
Jun 20, 2024 · DUBLIN, June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and...
Sep 12, 2023 · As Jazz Pharmaceuticals turns the page from its long-time growth driver Xyrem and leans on a trio of newer medicines for growth, its executive roster is undergoing some changes. The company’s...
Jun 28, 2022 · Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options.
Find the latest Jazz Pharmaceuticals plc (JAZZ) stock quote, history, news and other vital information to help you with your stock trading and investing.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.
Jazz’s GW Pharmaceuticals initiated clinical trials of Epidyolex in Japan in October 2022. The study tests the efficacy and safety of the drug in patients with LGS, DS and TSC. Suvecaltamide
2 days ago · In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $184.86, a high estimate of $222.00, and a low estimate of $113.00.
